皮下埋藏式灌注器腹腔化疗治疗中晚期消化道癌的临床观察

目的：探讨皮下埋藏式灌注器腹腔化疗治疗消化道恶性肿瘤的疗效。方法：将皮下埋藏式灌注器埋藏于腹壁下，其导管置于恶性肿瘤侵犯区内，于术后１～２周行灌注药物（５－ＦＵ、丝裂霉素），腹腔化疗６～９个疗程。结果：３１例消化道恶性肿瘤患者化疗后近期疗效显著。经ＣＴ、Ｂ超、ＧＩ检查随访１ａ，１７例（５４．８％）患者的恶性肿瘤阴影变小，８０．６％患者健康状态稳定。结论：术后皮下埋藏式灌注器腹腔化疗治疗消化道中晚期恶性肿瘤有良好疗效     

Diagnosis,treatment and outcome of spinal lymphoma in a pony

This report describes the diagnostic approach to, and treatment of, a case of severe pelvic limb ataxia in a Miniature Shetland pony. Diagnosis of an intradural‐extramedullary lesion at the level of T11–12 was made using CT myelography. Dorsolateral hemilaminectomy allowed surgical debulking of an intradural mass, diagnosed histopathologically as T cell rich B cell lymphoma. Post operative treatment with prednisolone, cytarabine and cyclophosphamide was tolerated well and the degree of ataxia reduced markedly, allowing the pony to return to normal management.     

Evaluation of ifosfamide salvage therapy for metastatic canine osteosarcoma

A retrospective study was performed to assess toxicity and response rate of ifosfamide salvage treatment for dogs diagnosed with metastatic osteosarcoma (OSA). Dogs diagnosed with OSA and previously treated with standard chemotherapy were included in the study. Nineteen dogs met the inclusion criteria, and 17 dogs were evaluable for response. Ifosfamide doses ranged from 375 to 425 mg m^?2 (median dose 375 mg m^?2), with a median of two doses administered per dog (range 1–7 doses). The overall response to ifosfamide was 11.8% [complete response (CR) = 1/17, partial response (PR) = 1/17, stable disease (SD) = 2/17, progressive disease (PD) = 13/17]. Two dogs were hospitalized due to ifosfamide toxicosis. The median survival duration from the first dose of ifosfamide to death was 95 days. Ifosfamide was well tolerated, but minor anti‐tumour activity was observed.     

Single-agent gemcitabine chemotherapy in dogs with hepatocellular carcinomas

The goal of this study was to determine the efficacy and tolerability of gemcitabine in dogs diagnosed with hepatocellular carcinoma (HCC). Eighteen dogs were examined retrospectively (4 massive HCC, 10 nodular HCC and 4 diffuse HCC). All dogs received gemcitabine at 350-400 mg m(-2) weekly for 5 weeks. Toxicity was graded using VCOG-CTCAE guidelines and response was monitored with serial abdominal ultrasounds. Fifteen dogs completed all five cycles. Toxicity was minimal and consisted of grade I/II vomiting, anorexia and diarrhoea and two episodes of grade III neutropenia. Median survival time for all dogs was 983 days. Median progression free interval was 971 days. Based on the results of this study, surgery remains the best treatment for HCC, despite incomplete resection. There was no improvement in the survival of those diagnosed with nonresectable HCC treated with gemcitabine chemotherapy.     

Comparison of two questionnaires to assess gastrointestinal toxicity in dogs and cats treated with chemotherapy*

Questionnaires completed by pet owners are widely used instruments to monitor adverse gastrointestinal (GI) effects in the owners' animals undergoing chemotherapy and for reporting toxicoses in clinical trials; however, no questionnaires have been formally evaluated. This study compares two questionnaire-based evaluations of adverse GI events: a basic, open-ended questionnaire and a detailed questionnaire modelled after the grading in the Veterinary Co-operative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE). Owners completed both questionnaires after their dog or cat received moderately emetogenic chemotherapy. Results were used to derive toxicity grades for anorexia, vomiting and diarrhoea. We evaluated 123 pairs of questionnaires. Disagreement in grade of anorexia, vomiting and diarrhoea was found in 24, 7 and 13% of paired questionnaires, respectively (κ = 0.63, 0.83 and 0.71, respectively). Although 'good' to 'very good' agreement was found, the potential for only 'fair' agreement between questionnaire methods is of concern and suggests a need to adopt a standardized form.     

Circadian protein Cry2 is a prognostic factor of colorectal cancer and a predictor of chemotherapy

AIM:To assess the association between the expression of Cry2 and the prognosis of colorectal cancer for determining the role of Cry2 in predicting the outcome of chemotherapy. METHODS:Sixteen primary colorectal cancer patients who consecutively underwent neoadjuvant chemotherapy with 5-fluorouracil were enrolled in the present study. The tumor specimens were obtained by colonscopy prior to treatment. The tumor response was evaluated by the response evaluation criteria in solid tumors(RECIST). Accordingly, the patients were divided into 2 groups:complete response(CR)/partial response(PR) and stable disease(SD)/progress disease(PD). Two-tail ² test was applied to analyze the data. In parallel, we assessed 307 patients, who underwent tumor resection between 2001 and 2005. Survival time was calculated from the date of surgery to the date of death or the last follow-up date. Survival curves were obtained by Kaplan-Meier method. Log-rank test was applied for univariate analysis. The Cox proportional hazards regression model was used to identify the independent prognostic factors. RESULTS:The expression of Cry2 was high in CR/PR patients and was low in SD/PD patients, with significant difference(P<0.05). The average survival time of the 84 patients with high expression of Cry2 was 83.458 months, while the average survival time of 223 patients with low expression of Cry2 was 100.10 months, also with significant difference(P<0.05). The patients with low expression of Cry2 lived longer. The multivariate Cox regression analysis indicated that the expression of Cry2 was an independent prognostic factor for colorectal cancer patients(HR was 1.70, 95% CI was 1.09 to 2.66, P<0.05). Multivariate Cox regression showed that high Cry2 expression predicted a worse prognosis(HR was 2.88, 95%CI was 1.03 to 8.06, P<0.05) in colorectal cancer patients with neoadjuvant chemotherapy. CONCLUSION:Expression of Cry2 is an independent prognostic factor for colorectal cancer patients. Lower expression of Cry2 indicates good response to neoadjuvant chemotherapy.     

Adjuvant anthracycline‐based vs metronomic chemotherapy vs no medical treatment for dogs with metastatic splenic hemangiosarcoma: A multi‐institutional retrospective study of the Italian Society of Veterinary Oncology

Treatment options for dogs with metastatic (stage III) splenic hemangiosarcoma are limited. A doxorubicin‐based chemotherapy regimen is commonly administered; however, there are no published data to support this practice. The aim of this study was to investigate the impact of maximum‐tolerated‐dose chemotherapy (MTD), metronomic chemotherapy (MC) and no adjuvant treatment on outcome in dogs with stage III splenic hemangiosarcoma undergoing splenectomy. Medical records of dogs with stage III splenic hemangiosarcoma that underwent splenectomy followed by MTD chemotherapy, MC or no adjuvant treatment were retrieved. Time to progression (TTP), survival time (ST) and toxicity were evaluated. One hundred three dogs were identified: 23 received adjuvant MTD, 38 MC and 42 were not medically treated. Overall median TTP and ST were 50 (95% confidence interval [CI], 39‐61) and 55 days (95% CI, 43‐66), respectively. Dogs treated with adjuvant MTD had a significantly longer TTP and ST compared with dogs receiving MC (median TTP, 134 vs 52 days, P = .025; median ST, 140 vs 58 days, P = .023, respectively). Dogs treated by splenectomy only had the shortest median TTP (28 days) and ST (40 days). However, treatment‐related adverse events (AEs) were significantly more frequent in the MTD group (P = .017). The outcome for dogs with metastatic splenic hemangiosarcoma is poor. While MTD showed greater efficacy compared to MC, toxicity was higher in this group. Treatment‐related AEs need to be carefully balanced against this modest survival prolongation when offering adjuvant MTD to dogs with advanced stage hemangiosarcoma.     

Cisplatin: a review of toxicities and therapeutic applications

Cisplatin is a platinum chemotherapeutic used in a variety of malignancies. The antineoplastic activity occurs from DNA cross‐links and adducts, in addition to the generation of superoxide radicals. Nephrotoxicity is the most well‐known and potentially most clinically significant toxicity. Unfortunately, the mechanism for cisplatin nephrotoxicity has not been completely elucidated; however, many theories have been developed. Other toxicities include gastrointestinal, myelosuppression, ototoxicity and neurotoxicity. Saline diuresis is currently the most accepted way to prevent cisplatin nephrotoxicity. Research has focused on pharmaceuticals and enzyme/molecular alterations as alternatives to long‐term diuresis. No agents have currently been identified that can protect from all toxicities. Cisplatin has shown activity against osteosarcoma, transitional cell carcinoma, squamous cell carcinoma (SCC), melanoma, mesothelioma, carcinomatosis and germinal cell tumours in the dog. In the cat, cisplatin cannot be utilized because of fulminant pulmonary oedema that occurs at standard doses. Intralesional cisplatin has been utilized in horses for the treatment of SCC and sarcoids.     

A Retrospective Study of Multi‐agent Chemotherapy including either Cyclophosphamide or Lomustine as Initial Therapy for Canine High‐grade T‐cell Lymphoma (2011‐2017)

Multi‐agent chemotherapy (vincristine, epirubicin and prednisolone) including either cyclophosphamide (CEOP) or lomustine (LEOP) was given as first‐line chemotherapy to treatment‐naïve canine lymphoma patients with measurable, high grade T‐cell lymphoma (HGTCL). All patients responded to either CEOP or LEOP. Toxicity was typical of multi‐agent chemotherapy protocols and 25% of dogs receiving lomustine exhibited mild‐to‐moderate ALT elevation and 29% grade 3 or 4 neutropenia. Median progression‐free survival (100 versus 269 days) and overall survival (155 versus 327 days) were significantly higher in patients receiving LEOP compared to CEOP. Overall survival was improved for patients receiving LEOP compared to those receiving CEOP followed by lomustine‐based rescue therapy. The results of this retrospective study support further evaluation of lomustine as part of first‐line, multi‐agent therapy for patients with HGTCL.